|
|
||||||||

* USDA, ARS Poisonous Plant Research Laboratory, and
and
Utah State University, Logan 84341
1 Correspondence:
1150 East 1400 North (phone 435-752-2941; fax 435-753-5681; E-mail:
bsteg{at}cc.usu.edu).
| Abstract |
|---|
|
|
|---|
Key Words: Delphinium Diterpenoid Alkaloids Kinetics Toxicity
| Introduction |
|---|
|
|
|---|
Most range cattle ingest sublethal amounts of larkspur without showing clinical toxicosis. Though such intoxications are unnoticed, larkspur toxins may be found in animal tissues and products. The purpose of this study is to compare the clinical signs of intoxication in mice with those of cattle and to describe the simple toxicokinetics of MLA in mice after a single intravenous dose.
| Materials and Methods |
|---|
|
|
|---|
Forty Swiss Webster male mice (Simonson Laboratories Inc., Gilroy, CA) weighing 35 ± 4 g were randomly divided into eight groups of five. These animals were also part of the control group of a vaccination trial that will be reported separately. The mice were dosed with purified MLA at a rate of 2.0 mg/kg of BW in the tail vein. This dose is 70% of the LD50, and should produce clinical signs but not be lethal (Manners et al., 1995). The MLA was extracted from Delphinium barbeyi and verified to be >99% pure via HPLC/electron spray mass spectrometry (ESMS) as described in the analysis section. The clinical signs of poisoning (demeanor, movement, coordination and neuromuscular function, respiration rate, and peripheral perfusion) were closely monitored. After injection, the groups were killed at 0, 1, 2, 5, 10, 15, 30, and 60 min after injection. Immediately afterward, the mice were necropsied. Serum, brain, liver, kidney, and skeletal muscle were collected and frozen at -20°C until analyzed. All animal work was done with the approval and under the supervision of the Utah State University Animal Care and Use Committee.
Sample Extractions
Tissue Samples. Frozen tissue (brain, muscle, kidney, and liver) was allowed to thaw at room temperature. Samples (0.2 to 0.3 g) were macerated with a razor blade, transferred to tared 8-mL screw-cap vials, and an exact weight of the sample was obtained. Two milliliters of 1% H2SO4 was added, and each sample was homogenized for 2 min. An additional 2 mL of 1% H2SO4 was added to the vials and the samples were mixed for 10 min. The samples were centrifuged for 20 min at 2,800 x g, and then decanted into 10-mL screw-cap test tubes. Five drops of concentrated NH4OH were then added from a Pasteur pipette to each sample. The samples were mixed and then extracted twice with 2 mL of CHCl3. After each extraction, the samples were spun in a centrifuge to aid layer separation, and the chloroform layer was removed with a Pasteur pipette and filtered through anhydrous Na2SO4 into a clean 7-mL screw-cap vial. The solvent was removed by evaporation under a flow of nitrogen at 70°C. The samples were then stored (-20°C) until analysis by HPLC/mass spectrometry (MS).
Serum Samples. Frozen serum samples were allowed to thaw at room temperature and then transferred to a tared 8-mL screw cap vials. One milliliter of phosphate buffer solution (137 mM NaCl, 2.7 mM KCl, and 10 mM phosphate buffer pH 7.4) was then added and the samples were mixed. One drop of concentrated NH4OH from a Pasteur pipette was then added to the samples. The samples were then extracted twice with CHCl3 using a procedure identical to the one stated above for the tissue samples.
Methyllycaconitine Assay
Sample and Standard Preparation. Samples were prepared for analysis by adding 1.0 mL of methanol/20 mM ammonium acetate (50:50) and mixing the samples for 10 to 15 min. The samples were then filtered through 0.2-µm nylon syringe filter into HPLC autosampler vials and capped.
Two sets of MLA standards to be used for calibration were prepared from a stock solution (20 ug/mL) of MLA in CHCl3 stored at -20°C. The high range set included standards at 500, 300, 150, 100, and 50 ng/mL and the low range set included standards at 50, 25, 10, and 5 ng/mL. All samples were initially analyzed with the high-range calibration by HPLC/ESMS. Samples found to contain MLA levels below 50 ng/mL were reanalyzed by HPLC/ESMS/MS with the low-range calibration set. New standards were analyzed after every 40 samples.
High-Performance Liquid Chromatography/Electrospray Mass Spectrometry Analysis. Analysis of MLA in the samples was accomplished using a HP 1100 binary HPLC system coupled to a Finnegan LCQ mass spectrometer (Finnegan MAT, San Jose, CA) with modification to the methods previously described (Turek et al., 1995; Gardner et al., 1999). Samples (20 µL) were injected with a HP 1100 autosampler onto a Betasil C18 HPLC column (100 x 2 mm, 5 µm, 100 A, Keystone Scientific, Bellefonte, PA). The column was eluted using an isocratic flow of methanol:20 mM ammonium acetate (65:35) at 0.5 mL/min. Retention time for MLA under these conditions was approximately 2.6 min, and the HPLC analysis was stopped after 5.5 min for a total recycle time between samples of approximately 6 min. Typically, the column was cleaned after 40 samples with 100% methanol followed by equilibration of the column with the isocratic solvent.
Flow from the HPLC was connected directly to the electrospray source of the Finnegan LCQ MS. The MS was operated in a full-scan MS mode (150 to 1,000 AMU) with the high-range calibration standards. Quantification of MLA was made from peak areas generated from the 683.3 (MH+, for MLA) extracted ion trace. Low range samples were analyzed operating the mass spectrometer in a selected product ion MS/MS mode and peak areas from the selected product ion 651.3 (MH+ - 32) trace was recorded for MLA quantitation.
Method Recovery. For the measurement of recovery, 0.3 g of the tissue analyzed was homogenized in 2 mL of 1% H2SO4. The sample was split into six aliquots. Methyllycaconitine standard (200 ng) was added to three of the aliquots, and the samples were analyzed as described above. The average percent recovery of the fortified samples was 95%.
Analysis and Statistics
The MLA concentrations were compared between groups and tissues using ANOVA in the GLM of SAS (SAS Inst., Inc., Cary, NC). Mean separations were determined using Duncans multiple-range test after a significant F-test at P < 0.05 (Proc GLM).
The MLA concentrations were plotted using SigmaPlot for Windows (version 5.0, SPSS Inc., Richmond, CA) and fitted to a biexponential equation of the form:
![]() |
The following parameters were determined:
Clt = Dose/AUC
(VD)ß = ClT/kelim
T1/2 = 0.693/kelim
Cmax
Tmax
Vp = Dose/A+B
Vt = VpXk12k21
k12 = AB(b - a)/(A+B)(Ab+Ba)
k21 = Ab+Ba/A+B
where C is the concentration of MLA in serum or tissue at time (t), A and B are preexponential coefficients, a and b are hybrid coefficients corresponding to the distribution and elimination phases, Vp and Vt are the apparent central and tissue compartment volumes, ClT is total-body clearance, (VD)ß is the apparent volume of distribution, t1/2 is the elimination half life, and Cmax - Tmax describes the concentration and time of maximal MLA concentrations. A trapezoidal method was used to determine the area under the curve (AUC) of a concentration vs. time graph.
| Results |
|---|
|
|
|---|
As seen in Table 1
and Figures 1 and 2![]()
, MLA concentrations peaked in the serum, liver, and brain within 1 min after dosing. The muscle and kidney were a little slower to reach peak concentrations, with highest MLA concentrations at 2 min. The kidney MLA concentrations were higher than other tissues at 5 min and tended to be higher through the rest of the study. The highest brain MLA concentrations were about 0.5 µg/g or about 25% the concentrations found in the other tissues.
|
|
|
|
| Discussion |
|---|
|
|
|---|
MLA distribution in tissues suggests that it is quickly redistributed from the vasculature into the liver, kidney, brain, and skeletal muscle (Table 1
). However, brain concentrations were only about 25% of that reached in other tissues, suggesting that MLA does not cross the blood brain barrier as easily as it crosses the vasculature of other tissues. Similar distribution studies are being conducted in other species to determine whether MLA has similarly decreased central nervous system accumulation.
The kidney has higher sustained MLA concentrations than other tissues. This suggests that MLA is actively concentrated and most likely excreted intact by the kidney. Clearance rates indicate that MLA is rapidly excreted. The half-life (t1/2) in the serum is about 17.46 min. Similar values have been observed in rats after a single i.v. dose (Turek et al., 1995). Renal elimination is slightly longer, with a t1/2 of 21.06 min and a t1/2 of 22.0 min in the liver. This suggests that MLA clearance of 99% from the tissue with the longest t1/2 (liver) would be accomplished in 154 min (seven half lives). Kinetics are likely to be vastly different after oral consumption of plant material because of the prolonged absorptive phase. Turek et al. (1995) showed that serum MLA clearances in rats dosed orally with MLA were 408 min or approximately 20 times longer than for i.v. doses. Longer clearance times are likely in animals grazing larkspur. After larkspur is in the flower and pod, cattle consume tall larkspur at relatively constant rates, which results in an equilibrium-like state. It is likely that such extended absorption phases and equilibrium states will affect elimination, which will prolong elimination of MLA. Studies in cattle are underway to determine these rates and to better define a withdrawal time in cattle under naturally occurring conditions.
| Implications |
|---|
|
|
|---|
Received for publication October 2, 2002. Accepted for publication January 8, 2003.
| Literature Cited |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
K. D. Welch, B. T. Green, K. E. Panter, D. R. Gardner, J. A. Pfister, D. Cook, and B. L. Stegelmeier Investigation of the susceptibility of various strains of mice to methyllycaconitine toxicosis J Anim Sci, April 1, 2009; 87(4): 1558 - 1564. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. X. Albuquerque, E. F. R. Pereira, M. Alkondon, and S. W. Rogers Mammalian Nicotinic Acetylcholine Receptors: From Structure to Function Physiol Rev, January 1, 2009; 89(1): 73 - 120. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. D. Welch, K. E. Panter, D. R. Gardner, B. T. Green, J. A. Pfister, D. Cook, and B. L. Stegelmeier The effect of 7,8-methylenedioxylycoctonine-type diterpenoid alkaloids on the toxicity of methyllycaconitine in mice J Anim Sci, October 1, 2008; 86(10): 2761 - 2770. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |